RBC Capital analyst Brian Abrahams downgraded Regeneron (REGN) to Sector Perform from Outperform with a price target of $662, down from $943.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Airbnb, Zscaler downgraded: Wall Street’s top analyst calls
- Regeneron downgraded to Equal Weight from Overweight at Wells Fargo
- Wells Fargo downgrades Regeneron after ‘disappointing’ itepekimab data
- Cautious Outlook on Regeneron: Mixed Itepekimab Results and Eylea Challenges Drive Sell Rating
- Regeneron, Sanofi: AERIFY-1 Phase 3 trial of itepekimab met primary endpoint